MDS Pharma Services (MDZ), the CRO headquartered in Canada, moved its Beijing lab to a much larger facility. The new 25,000 square foot space affords five times the space for testing, four times the space for producing clinical trial kits, and a greater number of clinical trial testing services. The new lab is also closer to the Beijing airport so clinical supplies can be transported easily.
In announcing the move, MDS noted that it was the first western CRO to own its testing facility in China. During the 10 years MDS has been operating in China, it has managed more than 30,000 patients in clinical trials.
The specialty of the new lab is molecular biology testing for infectious diseases, DNA banking and pharmacogenomics. It also offers enhanced molecular biology techniques, a microbiology lab and flow cytometry capabilities, which is used in oncology and immune disorders. MDS Pharma Services continues to offer project and data management.
Besides the Beijing facility, MDS offers services in Taipei, Taiwan.